Moderna, Inc. (MRNA)
| Market Cap | 138.04B |
| Revenue (ttm) | 2.73B |
| Net Income (ttm) | 598.17M |
| Shares Out | 400.00M |
| EPS (ttm) | 1.49 |
| PE Ratio | 229.16 |
| Forward PE | 13.99 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $341.90 |
| Previous Close | $349.32 |
| Change ($) | -7.42 |
| Change (%) | -2.12% |
| Day's Open | 351.00 |
| Day's Range | 336.00 - 351.22 |
| Day's Volume | 6,890,452 |
| 52-Week Range | 54.21 - 362.00 |
Moderna is riding high on the COVID-19 wave. Is it too late to get in?
Analysts' lowest price targets for these widely held stocks implies some serious downside.
It could equal billions in revenue for the company.
The biotech's sales and profits could exceed investors' expectations.
Moderna Inc (NASDAQ:MRNA) shares are trading higher by 6.2% at $348.47, rebounding after the stock dipped on Tuesday amid vaccine supply concerns. Vaccine stocks have also gained recently amid COVID-19 ...
It's a big stretch.
The writing could already be on the wall.
Moderna (NASDAQ:MRNA) shares are trading lower on reports suggesting the company is having supply issues. According to a Reuters report, the company said that it does not have a sufficient stock of vacc...
FDA Requests Pfizer and Moderna to Expand Pediatric Trials
The Food and Drug Administration has requested Pfizer and Moderna to test their COVID vaccines in more children before seeking authorization to help rule out safety issues. The expanded pediatric trials...
The FDA requested a larger clinical trial for the company's vaccine in younger kids.
The studies aim to spot rare side effects of the COVID-19 vaccine in younger recipients.
The vaccine makers were reportedly asked by the Food and Drug Administration to expand the size of their ongoing trials.
Moderna confirmed to CNBC on Monday it plans to expand the size of its clinical trial testing its Covid-19 vaccine in kids ages 5 to 11.
Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) will expand the size of ongoing COVID-19 vaccine trials in children ages five to 11 to detect potential rare side effects,...
Moderna entered the S&P 500 on July 21, 2021
#S&P500 #ModernaS&P500 Moderna replaced Alexion Pharmaceuticals Inc. in the S&P 500 effective prior to the opening of trading on Wed., July 21, according to a statement.
Once again, their high efficacy could mean more market share.
The biotech's sales and profits could soon receive another powerful boost.
Much focus on investment comes from the private sector, particularly those of the venture capitalist persuasion. But one of the biggest investors this country has is the federal government.
When insiders sell shares, it indicates their concern in the company's prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock.
The broader medical sector should gain on decent earnings expectations and higher COVID-19-related sales
It was a jarring start to the week for Wall Street, with stocks in a seeming freefall as a rise in global Covid-19 cases, specifically the delta variant, had many wondering if the smooth economic recove...
It comes after a study on more than 3,700 children.
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccine (Spikevax) f...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--EMA CHMP adopts positive opinion recommending authorization for the use of the Moderna COVID-19 vaccine in adolescents (12-17 years of age) in the EU.
The most important detail investors want to know wasn't revealed.
Past performance isn't necessarily indicative of future success -- but in this case it might just be.
Concerns about the delta variant are rising.
Moderna, Pfizer, and Johnson & Johnson are optimistic.
Moderna (MRNA) closed at $323.48 in the latest trading session, marking a +0.74% move from the prior day.
The company keeps scoring new supply deals across the Pacific.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces establishment of new charitable foundation.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces new supply agreement with Taiwan for 2022 and 2023.
Coronavirus variants will be the key variable.
Vaccination rates will determine what happens next.
There are four possible answers.
Fauci: Vaccines are safe and effective against delta variant
"We just need to get more and more people vaccinated," Dr. Anthony Fauci, chief medical advisor to President Biden, tells 'Closing Bell.' He emphasizes the need for data-based conclusions, like the fact...
Lexaria Bioscience Corp (NASDAQ: LEXX) has announced that its tolerability and pharmacokinetic study VIRAL-A20-3 has been completed with positive results. The study demonstrated that DehydraTECH enabled...
Dr. Vin Gupta explains why he's encouraging patients who received the single-shot J&J Covid vaccine to get a Pfizer or Moderna booster shot.
Moderna's stock dropped 2% in a volatile session on Tuesday, with the COVID-19 vaccine maker the most heavily traded company on Wall Street ahead of its debut in the S&P 500 on Wednesday.
The vaccine sector is in the spotlight again today, with Moderna Inc (NASDAQ:MRNA) at the masthead.
Stocks for companies developing or already distributing a vaccine for covid are on the move Tuesday and we've got all the details. The post Covid Vaccine Stocks: Why NVAX, OCGN, MRNA and QDEL Are on the...
Moderna stock rallied by more than 20% over the last week, significantly outperforming the S&P 500 which was down by about 1%. The recent rally comes as Moderna is set to be included in the S&P 500 inde...
Moderna, Inc. (NASDAQ: MRNA) shares appear to be going from strength to strength, and the premarket price action Tuesday suggests a positive open for the fifth straight session. What Happened: Cambridge...
It isn't about to get any cheaper anytime soon.
Even if you love these stocks, it may not be a bad move to cash out right now.
Moderna Inc (NASDAQ: MRNA) has announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and Takeda Pharmaceutical Co Ltd (NYSE: TAK) will purchase and distribute an additional 50 millio...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna partners with Takeda and the government of Japan to supply 50 million doses of Moderna's COVID-19 Vaccine & booster vaccine candidate in 2022.
The investment thesis for these high-flying stocks no longer holds water.
They could result in a broader market for Pfizer's vaccine.
About MRNA
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeu... [Read more...]
| Industry Biotechnology | IPO Date Dec 7, 2018 |
| CEO Stephane Bancel | Employees 1,300 |
| Stock Exchange NASDAQ | Ticker Symbol MRNA |
Financial Performance
In 2020, Moderna's revenue was $803.40 million, an increase of 1,234.34% compared to the previous year's $60.21 million. Losses were -$747.06 million, 45.3% more than in 2019.
Analyst Forecasts
According to 16 analysts, the average rating for Moderna stock is "Buy." The 12-month stock price forecast is 184.92, which is a decrease of -45.91% from the latest price.